Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023
 Financial highlights Direct MagnetOs sales grew by 163% to CHF 31.7 million in 2023, climbing from CHF 12.1 million…
 Financial highlights Direct MagnetOs sales grew by 163% to CHF 31.7 million in 2023, climbing from CHF 12.1 million…
Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced it wi…
 MagnetOs™ GranulÂes becomes the third product in the MagnetOs portfolio to receive FDA clearance to market for inter…
. New level 1 data from the MAXA Clinical Trial comparing standalone MagnetOs to the gold standard autograft in the ch…
 In the MAXA trial, standalone MagnetOs outperformed the gold standard autograft by 73% in posterior spinal fusion in…
 MagnetOs is the first open fibrillar collagen matrix bone graft substitute to receive clearance to market for interb…
 Direct MagnetOs sales grew to CHF 20.4 million in the first nine months of 2023, climbing from CHF 8.1 million in th…
. Financial Highlights Direct MagnetOs sales increased by 148% from CHF 4.9 million to CHF 12.2 million, total revenue…
In H1 2023, Lonza delivered CHF 3.1 billion sales and 5.6% CER1 sales growth, corresponding to around 10% CER underlying…
First investigational trial of drug-biologic bone graft for spinal fusion 50 patients have been enrolled in the Phase 2…